LEEP for High-Grade Cervical Intraepithelial Neoplasia (CIN 2-3)
LEEP is indicated for non-pregnant women with biopsy-confirmed CIN 2-3 or carcinoma in situ when the entire lesion and transformation zone are visible on colposcopy, and should be performed using loop electrodes under local anesthesia with colposcopic guidance to obtain a non-fragmented specimen with 3-mm negative margins. 1
Indications for LEEP
LEEP is appropriate for treating histologically confirmed high-grade squamous intraepithelial lesions (CIN 2-3) in non-pregnant women. The procedure serves dual purposes: diagnostic excision and definitive treatment 1.
Key requirements before proceeding:
- Biopsy-confirmed CIN 2-3 or carcinoma in situ
- Entire lesion visible colposcopically
- Transformation zone fully visualized
- No suspicion of invasive cancer
- Patient is not pregnant
The 2006 consensus guidelines establish that both ablative and excisional methods have similar overall failure rates (5-15%), but LEEP offers the distinct advantage of providing tissue for pathological examination 2.
Technique and Performance
The procedure should be performed as follows:
Preparation
- Perform under local anesthesia in outpatient setting 3, 4
- Use colposcopic guidance throughout 5, 4
- Select appropriate loop electrode size based on lesion extent
Excision Goals
- Obtain preferably a non-fragmented specimen 1
- Achieve 3-mm negative margins 1
- Ensure adequate depth to remove entire transformation zone
- Control excision depth using colposcopy with appropriately sized loop electrodes 4
Technical Considerations
Cold knife conization (CKC) is the preferred method for diagnostic excision, but LEEP is acceptable provided adequate margins and proper orientation are obtained 1. Large loop electrodes demonstrate superior success rates (90-94% for primary disease) compared to small loop electrodes (80%) 3.
Add endocervical curettage as clinically indicated 1.
Expected Outcomes and Success Rates
Treatment success (disease-free status) occurs in:
- 92% after single LEEP treatment 4
- 95% after repeat LEEP if needed 4
- 93-94% for primary CIN 2-3 using large loop electrodes 3
The procedure is well-tolerated with minimal discomfort under local anesthesia 3.
Complications and Management
Complication rates are low:
- Post-treatment bleeding: <2-7% of cases 3, 4
- Manage with recauterization or cervical packing
- Cervical stenosis: <1% 3
- Average blood loss: 3.6 mL (significantly less than laser conization at 11.2 mL) 6
Critical Pitfall: Margin Status
Positive or unclear margins significantly impact outcomes 5:
- Residual CIN occurs in 4.8% with positive margins vs. 2.6% with clear margins
- Recurrence occurs in 4.8% with positive margins vs. 0% with clear margins
- If margins are positive, perform repeat cone biopsy or trachelectomy 1
The margin status is the most important risk factor for residual and recurrent disease 5.
Special Considerations
"See and Treat" Approach
The see-and-treat approach (diagnosis and treatment in one visit) should be limited to cytologically and colposcopically unequivocal intraepithelial lesions 4. In doubtful cases, particularly in young patients, confirm disease with expert histology and colposcopy before definitive therapy 4.
Pregnancy
LEEP is contraindicated during pregnancy except for invasive cancer 2. CIN 2-3 has minimal risk of progression during pregnancy and high postpartum regression rates 2. However, recent data show LEEP within the first 15 weeks can be performed safely if absolutely necessary, though 5.2% of conservatively managed pregnant women with CIN 2-3 were ultimately diagnosed with invasive cancer 7.
Young Women
LEEP is particularly suitable for younger women who have not completed childbearing, with no cervical incompetence noted in subsequent pregnancies 6. The procedure preserves fertility while effectively treating disease.
Post-Treatment Follow-Up
HPV DNA testing demonstrates superior performance for post-treatment surveillance:
Follow-up is essential as treatment failure rates range from 5-15% across all modalities 2.